Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized with COVID-19 Pneumonia: A Randomized Clinical Trial

Jane A. O'Halloran, Emily R. Ko, Kevin J. Anstrom, Eyal Kedar, Matthew W. McCarthy, Reynold A. Panettieri, Martin Maillo, Patricia Segura Nunez, Anne M. Lachiewicz, Cynthia Gonzalez, P. Brian Smith, Sabina Mendivil Tuchia De Tai, Akram Khan, Alfredo J.Mena Lora, Matthias Salathe, Gerardo Capo, Daniel Rodríguez Gonzalez, Thomas F. Patterson, Christopher Palma, Horacio ArizaMaria Patelli Lima, John Blamoun, Esteban C. Nannini, Eduardo Sprinz, Analia Mykietiuk, Radica Alicic, Adriana M. Rauseo, Cameron R. Wolfe, Britta Witting, Jennifer P. Wang, Luis Parra-Rodriguez, Tatyana Der, Kate Willsey, Jun Wen, Adam Silverstein, Sean M. O'Brien, Hussein R. Al-Khalidi, Michael A. Maldonado, Richard Melsheimer, William G. Ferguson, Steven E. McNulty, Pearl Zakroysky, Susan Halabi, Daniel K. Benjamin, Sandra Butler, Jane C. Atkinson, Stacey J. Adam, Soju Chang, Lisa Lavange, Michael Proschan, Samuel A. Bozzette, William G. Powderly

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized with COVID-19 Pneumonia: A Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences